What Researchers Did
Researchers conducted a literature review to update the practical management of intractable haematuria within the UK's National Health Service.
What They Found
From 295 screened papers, researchers proposed a new treatment escalation plan for intractable haematuria. This plan suggests hyperbaric oxygen therapy as a second-line treatment option, following initial management and other first-line therapies like intravesical hyaluronic acid or tranexamic acid. They also noted that the evidence for most recommended treatments is weak, lacking robust randomized controlled trials.
What This Means for Canadian Patients
This review highlights hyperbaric oxygen therapy as a potential option for Canadian patients suffering from intractable haematuria when initial treatments fail. While this review is UK-specific, the proposed treatment pathway could inform discussions between Canadian patients and their healthcare providers about advanced options for this challenging condition.
Canadian Relevance
While this study is based on the UK National Health Service and does not feature Canadian authors, intractable haematuria is a condition affecting patients globally, including in Canada. Hyperbaric oxygen therapy, identified as a second-line treatment, is available in Canada and is often used for related conditions like radiation cystitis, which can cause severe haematuria.
Study Limitations
A key limitation noted by the researchers is the overall weak evidence base for most recommended treatments, stemming from a lack of appropriate randomized controlled trials.